Fig. 6. In vitro induced Tregs (iTregs) treated with miR-142-3p inhibitor results in reduced mortality and protects organs from immune damage in a xenogeneic model of graft-versus-host disease (xGVHD).

Human iTregs) from volunteers were expanded in vitro and were untreated or treated with miR-142-3p inhibitor or mimic for 3 days. Following treatment, iTregs (10 × 10⁶) and allogeneic peripheral blood mononuclear cells (PBMCs) (10 × 10⁶) were washed and transferred into NOD CRISPR Prkdc Il2r gamma (NCG) mice to test the efficacy to prevent xenogeneic graft-versus-host disease (GVHD). For the groups PBMC only, control, inhibitor, and mimic, n = 10, 10, 10, and 10, respectively. a Kaplan–Meier survival curves of results when mice injected with PBMC ± groups of iTregs (*P < 0.05, **P < 0.01). b Average clinical scores for GVHD for mice surviving on a given day for each group (*P < 0.05, **P < 0.01 for all iTreg groups from days 0 to 60). c Average weight (percentage of initial) for mice surviving on a given day for each group (**P < 0.01 for all iTreg groups from days 0 to 60). d In another independent xGVHD experiment, mice in the four groups were humanely killed on day 21; pathological tests using hematoxylin–eosin (HE) staining of the intestine, liver, and kidney were performed for each group (n = 3 per group). The results shown are representative of two independent xGVHD experiments. (*P<0.05 and **P<0.01)